Rubius Therapeutics, Inc.
Formerly VL26, Inc.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2018 | $101 M | No. 2 | $50 to $250 million | equity | SEC | |
| Jun 2017 | $115 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Rubius Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2018).
SEC Form D · Mar 2018
The industry group it chose in its notices: Biotechnology.
SEC Form D · Mar 2018
That is all the official record says: Rubius Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
In its own words
How the company describes itself to search engines on its website, word for word.
“Discover trusted Australia online casinos in 2025. Play pokies, live dealers, and games with fast payouts and rewarding bonuses.”
Source: The company's website · as of Nov 15, 2026
Products and services#
No products or services on record: its website does not describe any in structured form (a page that declares itself a product or service), and Wikidata lists none.
Investors#
7 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Flagship VentureLabs IV, LLC | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Flagship Ventures Fund IV General Partner LLC | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner, director (Form 3, 2018) | SEC Form 3 |
| Flagship Ventures Fund IV, L.P. | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Flagship Ventures Fund IV-Rx, L.P. | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Flagship Ventures Fund V, L.P. | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Flagship Ventures Opportunities Fund I, L.P. | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Flagship V VentureLabs Rx Fund, L.P. | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 27 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Andrew B. Oh | Executive officer | Mar 2018 |
| Christopher L. Carpenter | Executive officer | Mar 2018 |
| Joanne Protano | Executive officer | Mar 2018 |
| Torben Straight Nissen | Executive officer | Mar 2018 |
| Catherine B. Sohn | Director | Mar 2018 |
| David Straight Epstein | Director | Mar 2018 |
| Francis B. Cuss | Director | Mar 2018 |
| Michael S. Rosenblatt | Director | Mar 2018 |
| Noubar B. Afeyan | Director | Mar 2018 |
| Robert S. Langer | Director | Mar 2018 |
| Roger S. Pomerantz | Director | Mar 2018 |
| Torben Straight Nissen | Director | Mar 2018 |
| Harvey F. Lodish | Director | Jun 2017 |
| Michael Barton Rosenblatt | Director | Jun 2017 |
| Peter Barton Hutt | Director | Jun 2017 |
About
Company in Cambridge, United States.